Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Valion Bio, Inc. entered into Purchase Agreement with the Purchasers valued at approximately $1.8 million (effective 2023-07-10).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the Purchasers
- Value
- approximately $1.8 million
- Effective
- 2023-07-10
Exact text from the filing
On July 10, 2023, Tivic Health Systems, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the investors named on the signature pages thereto (the “Purchasers”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Valion Bio, Inc. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-07-10).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Maxim Group LLC
- Effective
- 2023-07-10
Exact text from the filing
On July 10, 2023, the Company and Maxim entered into a Placement Agency Agreement (the “Placement Agency Agreement”), pursuant to which, as compensation for services rendered by the Placement Agent in connection with the Offering, the Company paid the Placement Agent an aggregate cash fee of 8.0% of the aggregate gross proceeds of the Offering (amounting to $143,000) at closing, as well as $90,000 for the reimbursement of certain of the Placement Agent’s expenses.
View on SEC.gov